EUVIMEDEUVIMED entdecken
Systematische Übersicht

Biosimilars for the Treatment of Psoriasis

Duc Binh Phan, Sarah Elyoussfi, Michael Stevenson, Mark Lunt, Richard B Warren, Zenas Z N Yiu

JAMA Dermatology · 01.07.2023 · 159 (7) · 763

DOI: 10.1001/jamadermatol.2023.1338 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift JAMA Dermatology, erschienen am 01.07.2023. Verfasst von Duc Binh Phan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Dermatology Research, Northern Care Alliance NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre…. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Psoriasis. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Biosimilars have the potential to reduce costs for the management of moderate-to-severe psoriasis compared with originators. However, the extrapolation of evidence enables the approval of a biosimilar for use in indications held by the originator without directly being studied in clinical trials. Thus, biosimilars can be approved for psoriasis based on extrapolated evidence from other diseases. The availability of evidence for the effectiveness and safety of biosimilars for the treatment of psoriasis is therefore unclear.

Objective

To compare the efficacy/effectiveness and safety of biosimilars with originator biologics for the treatment of patients with psoriasis. Evidence Review MEDLINE, EMBASE, Cochrane Library, ClinicalTrials.gov, and The European Union Clinical Trials Register were searched in August 2022. Eligible studies were appraised using the Cochrane Risk of Bias 2 and ROBINS-I tools. All analyses were conducted from September 2022 to November 2022.

Findings

Fourteen trials (10 adalimumab, 2 etanercept, 1 infliximab, and 1 ustekinumab) and 3 cohort studies (1 adalimumab, 1 etanercept, 1 infliximab and etanercept) were included. Twelve trials compared biosimilars with originators in originator-naive patients (starters), and 11 trials compared switching from originator to biosimilar (switchers) with continuous originator treatments. There was no clinically or statistically significant difference in rates of achieving 75% improvement in Psoriasis Area and Severity Index scores and risks of adverse events (AEs) at week 16 and week 52 between the comparators. Two cohort studies showed no difference in effectiveness and safety outcomes between originators and biosimilars, whereas 1 study reported more AEs in patients who switched to biosimilars of adalimumab at 12 months. Three trials showed low risk of bias, whereas 11 trials had moderate risk of bias. All cohort studies had moderate to high risk of bias. Conclusions and Relevance In this systematic review, there was no clinically or statistically significant difference in the efficacy and safety between biosimilars and originators for the treatment of patients with psoriasis. Most of the available evidence was based on randomized clinical trials, although high-quality real-world evidence was lacking. Future studies are needed to examine the long-term effectiveness and safety of biosimilars for the treatment of patients with psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsPsoriasisHumansEtanerceptInfliximabAdalimumab

Substanzen

EtanerceptBiosimilar PharmaceuticalsInfliximabAdalimumab

Autor:innen und Institutionen

  • Centre for Dermatology Research, Northern Care Alliance NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, United Kingd…
  • The University of Manchester Library, The University of Manchester, Manchester, United Kingdom.
  • Versus Arthritis Epidemiology Unit, The University of Manchester, Manchester, United Kingdom.

Förderung

  • Department of Health

Zitieren

APA

Phan, D. B., Elyoussfi, S., Stevenson, M., Lunt, M., Warren, R. B., & Yiu, Z. Z. N. (2023). Biosimilars for the Treatment of Psoriasis. JAMA Dermatology, 159(7), 763. https://doi.org/10.1001/jamadermatol.2023.1338

Vancouver

Phan DB, Elyoussfi S, Stevenson M, Lunt M, Warren RB, Yiu ZZN. Biosimilars for the Treatment of Psoriasis. JAMA Dermatology. 2023;159(7):763. doi:10.1001/jamadermatol.2023.1338

BibTeX
@article{Phan2023,
  author = {Phan, Duc Binh and Elyoussfi, Sarah and Stevenson, Michael and Lunt, Mark and Warren, Richard B and Yiu, Zenas Z N},
  title = {Biosimilars for the Treatment of Psoriasis},
  journal = {JAMA Dermatology},
  year = {2023},
  volume = {159},
  number = {7},
  pages = {763},
  doi = {10.1001/jamadermatol.2023.1338}
}
Kostenlos starten →